Stem Cells SpinWAR:SCS 25 EV-to-FCF is -155.32 as of Jul. 03, 2026. GuruFocus rates WAR:SCS with a GF Score™ of 25/100 and a GF Value™ of zł0.10 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 332 Biotechnology companies, Stem Cells Spin ranks worse than 301204.52% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Stem Cells Spin's Enterprise Value is zł16.62 Mil.
Stem Cells Spin's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was zł-0.11 Mil. Therefore, Stem Cells Spin's EV-to-FCF for today is -155.32.
The historical rank and industry rank for Stem Cells Spin's EV-to-FCF or its related term are showing as below:
WAR:SCS'
s EV-to-FCF Range Over the Past 10 Years
Min: -1302.03 Med: 21.51 Max: 4204.85
Current: -155.32
During the past 13 years, the highest EV-to-FCF of Stem Cells Spin was 4204.85. The lowest was -1302.03. And the median was 21.51.
WAR:SCS's EV-to-FCF is ranked worse than 100% of 332
companies
in the Biotechnology industry
Industry Median: 16.26
vs WAR:SCS: -155.32
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Stem Cells Spin's PE Ratio (TTM) for today is calculated as:
Stem Cells Spin's share price for today is zł0.40.
Stem Cells Spin's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-0.014.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Stem Cells Spin EV-to-FCF Related Terms
Stem Cells Spin EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Stem Cells Spin's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Stem Cells Spin's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stem Cells Spin EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stem Cells Spin's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Stem Cells Spin's EV-to-FCF falls into.
Stem Cells Spin's current Enterprise Value is zł16.62 Mil.
Stem Cells Spin's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-0.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stem Cells Spin (WAR:SCS) has a EV-to-FCF of -155.32 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Stem Cells Spin and its competitors. According to the industry distribution chart, Stem Cells Spin ranks #999999 out of 332 companies in the Biotechnology industry.
Is Stem Cells Spin's EV-to-FCF too high?
Stem Cells Spin's current EV-to-FCF is -155.32. Based on the distribution chart, Stem Cells Spin ranks #999999 out of 332 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Stem Cells Spin has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stem Cells Spin's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stem Cells Spin ranks #999999 out of 332 companies for EV-to-FCF. This places Stem Cells Spin in the lower half of its industry. The industry median EV-to-FCF is 16.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.26, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Stem Cells Spin and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stem Cells Spin's current EV-to-FCF is -155.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stem Cells Spin stock overvalued right now?
Based on GuruFocus' analysis, Stem Cells Spin (WAR:SCS) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.10, compared to a current price of zł0.40 — trading 300% above its estimated fair value. The current EV-to-FCF is -155.32. Stem Cells Spin's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Stem Cells Spin (WAR:SCS), the current EV-to-FCF is -155.32 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stem Cells Spin (WAR:SCS) Overvalued in 2026?
Based on GuruFocus' analysis, Stem Cells Spin stock appears to be overvalued.
The current stock price of zł0.40 is trading 300% above its estimated GF Value™ of zł0.10.
GuruFocus considers Stem Cells Spin to be Significantly Overvalued.
Key valuation signals for WAR:SCS:
EV-to-FCF: -155.32
GF Value™: zł0.10 vs. price of zł0.40 (300% above fair value)
No single metric tells the full story. See the WAR:SCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing, and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1, and Velvetyna.
25GF Score
Get the complete analysis for WAR:SCS
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCS has been successfully added to your 
